MDS 2025: Plenary Session 6: Treatment Low Risk MDS (Part 1)

Session Chairs: Amy E. DeZern and Saskia Langemeijer EPO and Lenalidomide in MDS Non-del(5q) Hege K. Gravdahl Garelius EPO/Lenalidomide in MDS Del(5q) Maria D. Diez-Campelo Luspatercept and TGF beta pathway inhibition Pierre Fenaux Oral Abstracts: Data-Driven Clustering of Low Blasts Patients with Myelodysplastic Syndromes Reveals Biological Features Driving Differences in Prognosis Prediction Carlos Ruiz Arenas The Dark Side of Ring Sideroblasts in Myelodysplastic Neoplasms with Low Blasts Marco G. Raddi